< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 13 Feb 2021
Projects
1 - 10 of 14
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Augmenting THherapeutic Effectiveness through Novel AnalyticsFrom1 Apr 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Het KU Leuven Kankerinstituut (LKI): interdisciplinaire samenwerking ter bevordering van kankeronderzoek, kankerbehandeling en –zorg.From1 Jan 2020 → TodayFunding: BOF - research organisations
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → TodayFunding: Foundations, funds and other with scientific goal
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myelomaFrom1 Jan 2019 → TodayFunding: Foundations, funds and other with scientific goal
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myelomaFrom10 Sep 2018 → TodayFunding: FWO Strategic Basic Research Grant
- Clin-IC: Medtech solutions for patientsFrom1 May 2018 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- In search of novel working mechanisms of proteasome inhibitors in multiple myelomaFrom1 Oct 2015 → 13 Nov 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 222
- Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy(2022)
Authors: Peter Vandenberghe, Michel Delforge, Christophe Vandenbriele
Number of pages: 7 - Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma(2022)
Authors: Michel Delforge
Pages: 1309 - 1318Number of pages: 10 - Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.(2022)
Authors: Michel Delforge
Pages: 864 - Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?(2022)
Authors: Sarah Cappuyns, Alexander Van De Bruaene, Jan Bogaert, Lucienne Michaux, Michel Delforge
Number of pages: 10 - Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].(2022)
Authors: Michel Delforge
Pages: 117 - Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients(2022)
Authors: Michel Delforge, Peter Vandenberghe
Pages: 243 - 250Number of pages: 8 - COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network(2021)
Authors: Michel Delforge
Pages: E934 - E946Number of pages: 13 - Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial(2021)
Authors: Michel Delforge
Pages: 1378 - 1390Number of pages: 13 - Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study(2021)
Authors: Michel Delforge
Number of pages: 10 - Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study(2021)
Authors: Rosanne Janssens, Elise Schoefs, Martina Vandebroek, Michel Delforge, Steven Simoens, Isabelle Huys
Number of pages: 17